Fahed Al-Marzooqi Acquires VTVT Shares
Fahed Al-Marzooqi purchased 6,000 shares of VTVT, highlighting insider confidence.
Key Points
- Fahed Al-Marzooqi bought 6,000 shares of VTVT at $35.08 per share on June 26, 2026, for a total of $210,480.
- Shares of VTVT traded near $36.27 on Tuesday, with analysts maintaining a positive outlook.
- SAMSARA BIOCAPITAL and FMR LLC adjusted their holdings in VTVT, reflecting varied institutional interest.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Fahed Al-Marzooqi has made a significant move by purchasing 6,000 shares of VTVT at a price of $35.08 each on June 26, 2026. This acquisition amounts to a total value of $210,480. Such insider buying often signals a belief in the company's potential.
Insider Buying and Selling at vTv Therapeutics Inc.
On June 26, 2026, several insiders, including Fahed Al-Marzooqi, bought shares of VTVT. Al-Marzooqi acquired 6,000 shares at an average price of $35.08. Other insiders, such as AKKARAJU SRINIVAS, PHILLIPS ANNE, and SEKHRI PAUL, also made similar purchases, indicating a collective insider confidence in the company's future.
Other Institutional Activity in VTVT
Institutional investors have shown varied interest in VTVT. SAMSARA BIOCAPITAL, LLC held steady with 298,496 shares valued at approximately $11.8 million. FMR LLC reduced its stake by 8,465 shares, ending with 260,391 shares worth about $10.3 million, marking a 3.1% decrease. Meanwhile, MILLENNIUM MANAGEMENT LLC opened a new position with 206,288 shares valued at around $8.2 million. TRAILS EDGE CAPITAL PARTNERS, LP significantly reduced its holdings by 91,422 shares to 139,578 shares, a 39.6% decrease.
vTv Therapeutics Inc. Stock Up 12.1%
Shares of VTVT traded near $36.27 on Tuesday. While specific financial metrics for VTVT are not detailed, the stock's recent insider and institutional activity suggests a dynamic investment landscape.
$VTVT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analyst coverage of VTVT remains positive. On March 12, 2026, Evercore ISI Group initiated coverage with a 'buy' rating and a price target of $44. BTIG maintained its 'buy' rating with a target of $49 on January 27, 2026. Roth Capital also initiated coverage with a 'buy' rating and a target of $58. The consensus among analysts is bullish, reflecting strong expectations for VTVT's market performance.
Bottom Line
Fahed Al-Marzooqi's purchase of VTVT shares underscores insider confidence in the company's prospects. While insider transactions can be a good indicator of future performance, they are just one piece of the puzzle. Investors should also consider the broader context, including institutional moves and analyst ratings, to better understand VTVT's potential in the market.
Get vTv Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $VTVT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.